Symbols

AUTL

Autolus Therapeutics·NASDAQ

--(--)

AUTL Profile

Autolus Therapeutics Plc

A clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies

Industry

Biological Technology

Established Date

02/02/2018

Listing Date

06/22/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

752

Fiscal Year Ends

12-31

Website

www.autolus.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

The Mediaworks, 191 Wood Lane, London, W12 7FP, United Kingdom

Business

Introduction

Autolus Therapeutics plc was incorporated in England and Wales on February 2, 2018. The company is an early commercialization stage biopharmaceutical company developing next-generation T-cell therapies for cancer and autoimmune diseases. Its main product, AUCATZYL (obe-cel), is a chimeric antigen receptor T-cell therapy targeting CD19, which has been approved in the United States and the United Kingdom for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.